Christopher M. Starr's most recent trade in Monopar Therapeutics Inc was a trade of 16,800 Common Stock done at an average price of $0.0 . Disclosure was reported to the exchange on July 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Monopar Therapeutics Inc | Christopher M. Starr | Director | 14 Jul 2025 | 16,800 | 21,973 (0%) | 0% | 0.0 | 84 | Common Stock | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | 14 Jul 2025 | 16,800 | 0 | - | - | Stock Options | ||
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 14 Jul 2025 | 16,800 | 5,173 (0%) | 0% | 40.0 | 672,020 | Common Stock |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 11,365 | 11,365 | - | - | Stock Options | |
| Monopar Therapeutics Inc | M. Starr Christopher | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 2,533 | 25,863 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Starr M. Christopher | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 2,533 | 0 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 2,534 | 5,066 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 2,534 | 20,797 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,533 | 7,600 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,533 | 18,263 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 13,930 | 13,930 | - | - | Stock Options | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 10,133 | 10,133 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 2,859 | 0 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 2,859 | 15,730 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2022 | 2,859 | 12,871 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2022 | 2,859 | 2,859 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 2,859 | 10,012 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 2,859 | 5,718 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 2,859 | 8,577 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 2,859 | 7,153 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2021 | 752 | 2,792 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2021 | 752 | 1,502 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2021 | 751 | 2,040 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2021 | 751 | 2,254 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 4,443 | 4,443 | - | - | Stock Options | |
| Monopar Therapeutics Inc | Christopher M. Starr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 3,005 | 3,005 | - | - | Restricted Stock Units |